CO6311076A2 - Una composición que comprende 2-n-butil-3-[4-(3-di-n-butilaminopropoxi)benzoil]-5-metilsulfonamido-benzofurano y sus sales aceptables farmacéuticamente - Google Patents
Una composición que comprende 2-n-butil-3-[4-(3-di-n-butilaminopropoxi)benzoil]-5-metilsulfonamido-benzofurano y sus sales aceptables farmacéuticamenteInfo
- Publication number
- CO6311076A2 CO6311076A2 CO10133915A CO10133915A CO6311076A2 CO 6311076 A2 CO6311076 A2 CO 6311076A2 CO 10133915 A CO10133915 A CO 10133915A CO 10133915 A CO10133915 A CO 10133915A CO 6311076 A2 CO6311076 A2 CO 6311076A2
- Authority
- CO
- Colombia
- Prior art keywords
- pharmaceutically acceptable
- acceptable salts
- metilsulphonamide
- butilaminopropoxi
- butil
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/34—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide
- A61K31/343—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide condensed with a carbocyclic ring, e.g. coumaran, bufuralol, befunolol, clobenfurol, amiodarone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/06—Antiarrhythmics
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- General Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Engineering & Computer Science (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Furan Compounds (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Abstract
Utilización de dronedarona o una de sus sales aceptables farmacéuticamente para preparar un medicamento para el tratamiento de pacientes con arritmia, teniendo dichos pacientes un incremento en el nivel de creatinina debido a la administración de dronedarona, incrementándose dicho nivel de creatinina después del inicio del tratamiento con dronedarona, alcanzando dicho incremento del nivel de creatinina un plató y utilizándose como una línea base nueva, siendo dicho incremento del nivel de creatinina reversible después de la suspensión de la dronedarona.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US4873208P | 2008-04-28 | 2008-04-28 | |
EP08290407A EP2116239A1 (en) | 2008-04-29 | 2008-04-29 | Method for managing the risks associated with an increase in serum creatinine during dronedarone treatment |
Publications (1)
Publication Number | Publication Date |
---|---|
CO6311076A2 true CO6311076A2 (es) | 2011-08-22 |
Family
ID=39680951
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CO10133915A CO6311076A2 (es) | 2008-04-28 | 2010-10-28 | Una composición que comprende 2-n-butil-3-[4-(3-di-n-butilaminopropoxi)benzoil]-5-metilsulfonamido-benzofurano y sus sales aceptables farmacéuticamente |
Country Status (27)
Country | Link |
---|---|
US (1) | US20100016423A1 (es) |
EP (2) | EP2116239A1 (es) |
JP (1) | JP2011518872A (es) |
KR (1) | KR20100135853A (es) |
CN (1) | CN102076337A (es) |
AR (1) | AR072954A1 (es) |
AU (1) | AU2009241286A1 (es) |
BR (1) | BRPI0912706A2 (es) |
CA (1) | CA2722815A1 (es) |
CL (1) | CL2009001018A1 (es) |
CO (1) | CO6311076A2 (es) |
DO (1) | DOP2010000327A (es) |
EA (1) | EA201071138A1 (es) |
EC (1) | ECSP10010567A (es) |
IL (1) | IL208900A0 (es) |
MA (1) | MA32299B1 (es) |
MX (1) | MX2010011873A (es) |
NI (1) | NI201000181A (es) |
NZ (1) | NZ588886A (es) |
PA (1) | PA8824601A1 (es) |
PE (1) | PE20091885A1 (es) |
SG (1) | SG188180A1 (es) |
TW (1) | TW200948355A (es) |
UA (1) | UA100883C2 (es) |
UY (1) | UY31790A (es) |
WO (1) | WO2009133470A2 (es) |
ZA (1) | ZA201007727B (es) |
Families Citing this family (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP2280701A2 (en) * | 2008-04-17 | 2011-02-09 | Sanofi-Aventis | Use of dronedarone for the preparation of a medicament for use in the prevention of cardiovascular hospitalization or of mortality |
FR2930149B1 (fr) * | 2008-04-17 | 2011-02-18 | Sanofi Aventis | Association de dronedarone avec au moins un diuretique, son application en therapeutique |
FR2959132A1 (fr) * | 2010-04-22 | 2011-10-28 | Sanofi Aventis | Procedes pour l'evaluation et la reduction des risques |
US8602215B2 (en) | 2010-06-30 | 2013-12-10 | Sanofi | Methods for reducing the risk of an adverse dronedarone/beta-blockers interaction in a patient suffering from atrial fibrillation |
EP2605758A2 (en) * | 2010-08-17 | 2013-06-26 | Lupin Limited | Controlled release formulations of dronedarone |
RU2456019C1 (ru) * | 2011-03-29 | 2012-07-20 | Государственное образовательное учреждение высшего профессионального образования "Пермская государственная медицинская академия имени академика Е.А. Вагнера Федерального агентства по здравоохранению и социальному развитию" | Способ прогнозирования развития жизнеопасных желудочковых аритмий у пациентов без структурных изменений сердца |
Family Cites Families (34)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4868179A (en) * | 1987-04-22 | 1989-09-19 | Cohn Jay N | Method of reducing mortality associated with congestive heart failure using hydralazine and isosorbide dinitrate |
FR2665444B1 (fr) | 1990-08-06 | 1992-11-27 | Sanofi Sa | Derives d'amino-benzofuranne, benzothiophene ou indole, leur procede de preparation ainsi que les compositions les contenant. |
FR2735365B1 (fr) * | 1995-06-14 | 1997-09-05 | Sanofi Sa | Utilisation d'un antagoniste de l'angiotensine ii et d'un derive du benzofurane pour la preparation d'un medicament utile dans le traitement des affections cardiovasculaires |
FR2746013B1 (fr) * | 1996-03-18 | 1998-05-29 | Sanofi Sa | Utilisation de composes antiarythmiques dans la prevention de la mortalite post infarctus |
FR2764800B1 (fr) * | 1997-06-23 | 1999-09-10 | Sanofi Sa | Composition pharmaceutique solide contenant des derives de benzofuranne |
US6897305B2 (en) * | 1998-06-08 | 2005-05-24 | Theravance, Inc. | Calcium channel drugs and uses |
BR9915134A (pt) * | 1998-11-06 | 2001-08-07 | Searle & Co | Co-terapia e terapia combinada para o tratamento de distúrbio cardiovascular em um indivìduo, e, composição |
US20030113330A1 (en) * | 1999-11-08 | 2003-06-19 | Uhal Bruce D. | Methods for treating pulmonary fibrosis |
US6411840B1 (en) * | 1999-11-16 | 2002-06-25 | Cardiac Intelligence Corporation | Automated collection and analysis patient care system and method for diagnosing and monitoring the outcomes of atrial fibrillation |
FR2803846B1 (fr) * | 2000-01-17 | 2002-04-05 | Clariant France Sa | 3-(1-hydroxy-pentylidene)-5-nitro-3h-benzofuran-2-one, son procede de preparation et son utilisation |
GB0020691D0 (en) * | 2000-08-22 | 2000-10-11 | Boehringer Ingelheim Pharma | Pharmaceutical combination |
FR2817865B1 (fr) * | 2000-12-11 | 2005-02-18 | Sanofi Synthelabo | Derive aminoalkoxybenzoyle sous forme de sel, son procede de preparation et son utilisation comme intermediaire de synthese |
FR2817750B1 (fr) * | 2000-12-11 | 2003-02-21 | Sanofi Synthelabo | Composition pharmaceutique de dronedarone pour administration parenterale |
FR2817864B1 (fr) * | 2000-12-11 | 2003-02-21 | Sanofi Synthelabo | Derive de methanesulfonamido-benzofurane, son procede de preparation et son utilisation comme intermediaire de synthese |
US7022343B2 (en) * | 2000-12-27 | 2006-04-04 | Genzyme Corporation | Controlled release of anti-arrhythmic agents |
US6831102B2 (en) * | 2001-12-07 | 2004-12-14 | Bristol-Myers Squibb Company | Phenyl naphthol ligands for thyroid hormone receptor |
US20030229007A1 (en) * | 2002-05-30 | 2003-12-11 | Roberto Levi | Form of human renin and its use as a target in treatments for cardiac ischemia and arrhythmia |
DE10237819A1 (de) * | 2002-08-19 | 2004-03-04 | Bayer Ag | 5-Nitrobenzofurane |
US20050004194A1 (en) * | 2003-05-15 | 2005-01-06 | Graves Kurt Chum | Use of organic compounds |
US20060093673A1 (en) * | 2003-06-27 | 2006-05-04 | Coury Arthur J | Controlled release of anti-arrhythmic agents |
US7674820B2 (en) * | 2003-08-07 | 2010-03-09 | Cardiome Pharma Corp. | Ion channel modulating activity I |
US7820702B2 (en) * | 2004-02-04 | 2010-10-26 | Bristol-Myers Squibb Company | Sulfonylpyrrolidine modulators of androgen receptor function and method |
US20050182105A1 (en) * | 2004-02-04 | 2005-08-18 | Nirschl Alexandra A. | Method of using 3-cyano-4-arylpyridine derivatives as modulators of androgen receptor function |
US7772232B2 (en) * | 2004-04-15 | 2010-08-10 | Bristol-Myers Squibb Company | Quinazolinyl compounds as inhibitors of potassium channel function |
FR2875409B1 (fr) * | 2004-09-17 | 2010-05-07 | Sanofi Aventis | Composition pharmaceutique comprenant une dispersion solide a matrice polymere comprenant une phase continue de polydextrose et une phase continue d'un polymere autre que du polydextrose |
GB0611210D0 (en) * | 2006-06-07 | 2006-07-19 | Cambrex Karlskoga Ab | Process |
DE102006035912A1 (de) * | 2006-07-31 | 2008-02-07 | Südzucker AG Mannheim/Ochsenfurt | Verwendung von Isomaltulose in regenerativ wirkenden Nahrungsmitteln |
US20090076137A1 (en) * | 2007-09-19 | 2009-03-19 | Protia, Llc | Deuterium-enriched dronedarone |
EP2280701A2 (en) * | 2008-04-17 | 2011-02-09 | Sanofi-Aventis | Use of dronedarone for the preparation of a medicament for use in the prevention of cardiovascular hospitalization or of mortality |
FR2930149B1 (fr) * | 2008-04-17 | 2011-02-18 | Sanofi Aventis | Association de dronedarone avec au moins un diuretique, son application en therapeutique |
FR2930150B1 (fr) * | 2008-06-24 | 2011-01-14 | Sanofi Aventis | Utilisation de la dronedarone pour la preparation d'un medicament destine a reguler le taux de potassium dans le sang |
EP2133074A1 (en) * | 2008-06-10 | 2009-12-16 | Sanofi-Aventis | Use of dronedarone for the preparation of a medicament intended for the prevention of permanent atrial fibrillation |
EP2133075A1 (en) * | 2008-06-10 | 2009-12-16 | Sanofi-Aventis | Use of dronedarone for the preparation of a medicament intended for the prevention of cardioversion |
EP2153830A1 (en) * | 2008-08-07 | 2010-02-17 | Sanofi-Aventis | Use of dronedarone for the preparation of a medicament intended for the prevention of stroke or transient ischemic attack |
-
2008
- 2008-04-29 EP EP08290407A patent/EP2116239A1/en not_active Withdrawn
-
2009
- 2009-04-27 AR ARP090101485A patent/AR072954A1/es not_active Application Discontinuation
- 2009-04-28 BR BRPI0912706A patent/BRPI0912706A2/pt not_active IP Right Cessation
- 2009-04-28 PE PE2009000576A patent/PE20091885A1/es not_active Application Discontinuation
- 2009-04-28 NZ NZ588886A patent/NZ588886A/xx not_active IP Right Cessation
- 2009-04-28 CA CA2722815A patent/CA2722815A1/en not_active Abandoned
- 2009-04-28 JP JP2011506799A patent/JP2011518872A/ja active Pending
- 2009-04-28 CN CN2009801248266A patent/CN102076337A/zh active Pending
- 2009-04-28 EA EA201071138A patent/EA201071138A1/ru unknown
- 2009-04-28 EP EP09738483A patent/EP2291183A2/en not_active Withdrawn
- 2009-04-28 MX MX2010011873A patent/MX2010011873A/es not_active Application Discontinuation
- 2009-04-28 CL CL2009001018A patent/CL2009001018A1/es unknown
- 2009-04-28 KR KR1020107024051A patent/KR20100135853A/ko not_active Application Discontinuation
- 2009-04-28 SG SG2013013537A patent/SG188180A1/en unknown
- 2009-04-28 UA UAA201012809A patent/UA100883C2/ru unknown
- 2009-04-28 AU AU2009241286A patent/AU2009241286A1/en not_active Abandoned
- 2009-04-28 WO PCT/IB2009/005930 patent/WO2009133470A2/en active Application Filing
- 2009-04-29 US US12/431,830 patent/US20100016423A1/en not_active Abandoned
- 2009-04-29 UY UY0001031790A patent/UY31790A/es not_active Application Discontinuation
- 2009-04-29 PA PA20098824601A patent/PA8824601A1/es unknown
- 2009-04-29 TW TW098114259A patent/TW200948355A/zh unknown
-
2010
- 2010-10-24 IL IL208900A patent/IL208900A0/en unknown
- 2010-10-26 EC EC2010010567A patent/ECSP10010567A/es unknown
- 2010-10-27 NI NI201000181A patent/NI201000181A/es unknown
- 2010-10-28 ZA ZA2010/07727A patent/ZA201007727B/en unknown
- 2010-10-28 CO CO10133915A patent/CO6311076A2/es not_active Application Discontinuation
- 2010-10-28 DO DO2010000327A patent/DOP2010000327A/es unknown
- 2010-11-11 MA MA33340A patent/MA32299B1/fr unknown
Also Published As
Publication number | Publication date |
---|---|
CN102076337A (zh) | 2011-05-25 |
NI201000181A (es) | 2012-03-15 |
PA8824601A1 (es) | 2009-12-16 |
UY31790A (es) | 2009-12-14 |
US20100016423A1 (en) | 2010-01-21 |
TW200948355A (en) | 2009-12-01 |
AR072954A1 (es) | 2010-10-06 |
CA2722815A1 (en) | 2009-11-05 |
EP2116239A1 (en) | 2009-11-11 |
MX2010011873A (es) | 2011-04-05 |
CL2009001018A1 (es) | 2011-01-07 |
BRPI0912706A2 (pt) | 2017-06-13 |
SG188180A1 (en) | 2013-03-28 |
MA32299B1 (fr) | 2011-05-02 |
DOP2010000327A (es) | 2011-01-31 |
ECSP10010567A (es) | 2010-11-30 |
ZA201007727B (en) | 2013-01-30 |
IL208900A0 (en) | 2011-01-31 |
EA201071138A1 (ru) | 2011-06-30 |
EP2291183A2 (en) | 2011-03-09 |
NZ588886A (en) | 2013-01-25 |
PE20091885A1 (es) | 2009-12-31 |
UA100883C2 (ru) | 2013-02-11 |
JP2011518872A (ja) | 2011-06-30 |
WO2009133470A2 (en) | 2009-11-05 |
KR20100135853A (ko) | 2010-12-27 |
AU2009241286A1 (en) | 2009-11-05 |
WO2009133470A3 (en) | 2009-12-23 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CL2011002697A1 (es) | Compuestos derivados de 3-[4-(oxo-dihidropiridin)bencil]-1,3-oxazin-ona hidratados, inhibidores 11beta-hsd1; composicion farmaceutica que los comprende; y su uso en el tratamiento de la diabetes | |
CL2015002680A1 (es) | Composición farmaceutica que comprende un activador de ampk y un agente serotoninérgico y método para usar los mismos | |
CL2015002608A1 (es) | Compuesto de amino-pirazol y usos medicinales relacionados. | |
DOP2017000156A (es) | Derivados de glucagón con estabilidad mejorada | |
CL2008002999A1 (es) | Uso de una composicion farmeceutica que comprende trns-clominefo para preparar un medicamenteo util en el ratamiento de recuccion de los niveles de glucosa en ayunas en un varon. | |
AR096892A1 (es) | Una combinación farmacéutica para el tratamiento del melanoma | |
CL2012003053A1 (es) | Combinacion farmaceutica que comprende un agonista del receptor glp-1 y linagliptin, inhibidor dpp-4; uso de la combinacion farmaceutica para el tratamiento de la diabetes tipo 2 y de la obesidad. | |
PE20141906A1 (es) | Esketamina para el tratamiento de la depresion refractaria al tratamiento o resistente al tratamiento | |
CO6491060A2 (es) | Compuestos y composiciones para el tratamiento de enfermedades parasitarias | |
CL2015000294A1 (es) | Combinaciones farmaceuticas que comprenden un inhibidor de b-raf, un inhibidor del receptor del factor de crecimiento epidermico y opcionalmente un inhibidor pi3halpha y uso en el tratamiento de una enfermedad proliferativa. | |
CO6311076A2 (es) | Una composición que comprende 2-n-butil-3-[4-(3-di-n-butilaminopropoxi)benzoil]-5-metilsulfonamido-benzofurano y sus sales aceptables farmacéuticamente | |
CL2011000798A1 (es) | Uso de etexilato de dabigatran o una sal del mismo para preparar un medicamento util para la prevencion del ictus en pacientes que padecen fibrilacion auricular. | |
CL2011000806A1 (es) | Uso de etexilato de dabigatran o una sal del mismo para preparar un medicamento util para la prevencion del ictus en pacientes que padecen fibrilacion auricular. | |
CL2019002900A1 (es) | Análogos de benzoazepina como agentes inhibidores de la tirosina cinasa de bruton. | |
ECSP11011076A (es) | Tratamiento de trastornos cognitivos con (r)-7-cloro-n-(quinuclidin-3-il)benzo[b]tiofeno-2-carboxamida y sales farmacéuticamente aceptables de la misma | |
ECSP16086247A (es) | (s)-pirlindole y sus sales farmacéuticamente aceptables para uso en medicina | |
CL2020000019A1 (es) | Agentes de iarn para la inhibición de la expresión de alfa-enac y métodos de uso. | |
CO7461127A2 (es) | Código para la configuración de un dispositivo de atención al paciente | |
CO6361995A2 (es) | Derivados de isoquinolinona como antagonistas de nk3 | |
ES2616035T3 (es) | Preparación para su uso en la profilaxis y el tratamiento de osteoporosis atípica | |
CL2009001841A1 (es) | Uso de una composición de liberación sostenida de 4-aminopiridina para preparar un medicamento útil para tratar esclerosis multiple en un sujeto. | |
ECSP10010464A (es) | Uso de ranolazina para el tratamiento de enfermedades cardiovasculares | |
ECSP16086232A (es) | (r) -pirlindole y sus sales farmacéuticamente aceptables para uso en medicina | |
AR082501A1 (es) | Usos terapeuticos de 1-[2-(2,4-dimetil-fenilsulfanil)fenil]piperazina | |
CL2015001574A1 (es) | Terapia combinada para el cancer |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
FC | Application refused |